1075 related articles for article (PubMed ID: 32710969)
1. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
Lisi L; Lacal PM; Barbaccia ML; Graziani G
Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
[TBL] [Abstract][Full Text] [Related]
2. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
3. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
6. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
8. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
mBio; 2020 May; 11(3):. PubMed ID: 32444382
[TBL] [Abstract][Full Text] [Related]
10. Tackling SARS-CoV-2: proposed targets and repurposed drugs.
Joshi S; Joshi M; Degani MS
Future Med Chem; 2020 Sep; 12(17):1579-1601. PubMed ID: 32564623
[TBL] [Abstract][Full Text] [Related]
11. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
13. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
[TBL] [Abstract][Full Text] [Related]
14. Old and re-purposed drugs for the treatment of COVID-19.
Jean SS; Hsueh PR
Expert Rev Anti Infect Ther; 2020 Sep; 18(9):843-847. PubMed ID: 32419524
[No Abstract] [Full Text] [Related]
15. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
16. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.
Saul S; Einav S
ACS Infect Dis; 2020 Sep; 6(9):2304-2318. PubMed ID: 32687696
[TBL] [Abstract][Full Text] [Related]
17. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
Chakraborti S; Bheemireddy S; Srinivasan N
Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772
[TBL] [Abstract][Full Text] [Related]
18. An overview of potential therapeutic agents to treat COVID-19.
Dong X; Tian Z; Shen C; Zhao C
Biosci Trends; 2020 Nov; 14(5):318-327. PubMed ID: 33100290
[TBL] [Abstract][Full Text] [Related]
19. Drug repurposing and cytokine management in response to COVID-19: A review.
Heimfarth L; Serafini MR; Martins-Filho PR; Quintans JSS; Quintans-Júnior LJ
Int Immunopharmacol; 2020 Nov; 88():106947. PubMed ID: 32919216
[TBL] [Abstract][Full Text] [Related]
20. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds.
Tzou PL; Tao K; Nouhin J; Rhee SY; Hu BD; Pai S; Parkin N; Shafer RW
Viruses; 2020 Sep; 12(9):. PubMed ID: 32916958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
